Diphenhydramine
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Diphenhydramine: From Allergy Relief to Rosacea Conjunctivitis
One-Sentence Summary
Diphenhydramine is a widely marketed over-the-counter drug. Its US product names point to allergy relief and nighttime sleep aid, though the data contain no approved indication text. The TxGNN model predicts it may be effective for rosacea conjunctivitis, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergy relief / sleep aid (inferred from product names; no indication text in the data) |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Diphenhydramine is generally known as a first-generation H1 antihistamine, and its use in allergy products suggests it relieves histamine-mediated symptoms. Mechanistically, it might ease itching or redness of the eye.
That link is weak and speculative. Ocular rosacea is mainly an inflammatory and meibomian gland disorder, not primarily a histamine-driven one. The high TxGNN score (99.20%) is a model output and is not clinical evidence. It should be treated as a hypothesis to test, not a finding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The data list 20 authorizations in total. Five are shown below, and none includes approved indication text.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| M012 | DG Health Allergy | Tablet | Dolgencorp Inc |
| M012 | Childrens Allergy Relief | Chewable tablet | Walmart Inc. |
| M012 | Nighttime Sleep Aid | Tablet | Bi-Mart |
| M012 | Quality Choice Allergy Relief | Liquid-filled capsule | Chain Drug Marketing Association |
| M012 | CVS Diphenhydramine Hydrochloride | Tablet | CVS Pharmacy |
Other marketed forms include capsule, coated tablet, solution, spray, liquid and injection. None is identified as an ophthalmic product.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or literature (Evidence Level L5). The mechanistic link between an H1 antihistamine and ocular rosacea is weak, and the safety and mechanism data are missing.
To proceed, the following is needed:
- Package insert warnings and contraindications, which currently block safety screening
- Mechanism of action data (for example, from DrugBank)
- A literature and trial search on antihistamines in ocular rosacea and blepharoconjunctivitis
- Confirmation of a suitable route of administration, since no ophthalmic formulation is identified in the current data
- Preclinical or mechanistic evidence of a role for histamine in rosacea conjunctivitis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.